Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Expert Opinion on Drug Metabolism & Toxicology
|
April 5, 2013
Microdosing and drug development: past, present and future
Graham Lappin, Robert Noveck, Tal Burt
Immunopharmacology and Immunotoxicology
|
August 1, 2008
Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide
Edward Shannon, Robert Noveck, Felipe Sandoval, et al.
Innate Immunity
|
November 29, 2008
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
Daniel P Rossignol, Nancy Wong, Robert Noveck, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
October 30, 2007
Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia
Edward Shannon, Robert Noveck, Felipe Sandoval, et al.
Drugs in R&D
|
January 26, 2007
Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects
Gopal Krishna, Robert Noveck, Ramon Vargas, et al.
Journal of Pain and Symptom Management
|
June 30, 2004
Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee
Najib Babul, Robert Noveck, Howard Chipman, et al.
Journal of Clinical Pharmacology
|
November 10, 2010
Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach
Cathye Shu, Honghui Zhou, Mehri Afsharvand, et al.
Journal of Clinical Pharmacology
|
September 5, 2002
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers
Keith D Wilner, Margaret Rushing, Catherine Walden, et al.
Journal of Clinical Pharmacology
|
March 26, 2019
The Potential Role of the J-T<sub>peak</sub> Interval in Proarrhythmic Cardiac Safety: Current State of the Science From the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium
Jose Vicente, David G Strauss, Vijay V Upreti, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 21, 2013
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
Jeanne Mendell, Hamim Zahir, Nobuko Matsushima, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Expert Opinion on Drug Metabolism & Toxicology
|
April 5, 2013
Microdosing and drug development: past, present and future
Graham Lappin, Robert Noveck, Tal Burt
Immunopharmacology and Immunotoxicology
|
August 1, 2008
Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide
Edward Shannon, Robert Noveck, Felipe Sandoval, et al.
Innate Immunity
|
November 29, 2008
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers
Daniel P Rossignol, Nancy Wong, Robert Noveck, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine
|
October 30, 2007
Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia
Edward Shannon, Robert Noveck, Felipe Sandoval, et al.
Drugs in R&D
|
January 26, 2007
Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects
Gopal Krishna, Robert Noveck, Ramon Vargas, et al.
Journal of Pain and Symptom Management
|
June 30, 2004
Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee
Najib Babul, Robert Noveck, Howard Chipman, et al.
Journal of Clinical Pharmacology
|
November 10, 2010
Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach
Cathye Shu, Honghui Zhou, Mehri Afsharvand, et al.
Journal of Clinical Pharmacology
|
September 5, 2002
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers
Keith D Wilner, Margaret Rushing, Catherine Walden, et al.
Journal of Clinical Pharmacology
|
March 26, 2019
The Potential Role of the J-T<sub>peak</sub> Interval in Proarrhythmic Cardiac Safety: Current State of the Science From the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium
Jose Vicente, David G Strauss, Vijay V Upreti, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|
June 21, 2013
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
Jeanne Mendell, Hamim Zahir, Nobuko Matsushima, et al.
Page
of 2